New hope for rare skin condition: apremilast trial shows promise
Disease control
Completed
This study tested a drug called apremilast (Otezla) in 8 people with chronic, treatment-resistant erythema multiforme, a painful skin and mucous membrane condition. The goal was to see if the drug could reduce the number and pain of flare-ups over 6 months. Participants took the …
Phase: PHASE2 • Sponsor: Robert Micheletti • Aim: Disease control
Last updated May 15, 2026 11:53 UTC